Evidence map›Paper›PMID 36941508›Full record

Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2023

Characterization of a multidisciplinary team's role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia.

Vera Pervitsky, Julie Guglielmo, Benjamin Moskoff, Roxie Kneen, Carol Leija, Deborah Sawicky, Margaret Li Krackeler, Brian A Jonas, Ryan Beechinor

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Vera PervitskyDepartment of Pharmacy, University of California Davis Medical Center, Sacramento, CA, USA.
Julie GuglielmoDepartment of Pharmacy, University of California Davis Medical Center, Sacramento, CA, USA.
Benjamin MoskoffDepartment of Pharmacy, University of California Davis Medical Center, Sacramento, CA, USA.
Roxie KneenUC Davis Comprehensive Cancer Center, 2279 45th Street, CA, 95817, Sacramento, USA.
Carol LeijaUC Davis Comprehensive Cancer Center, 2279 45th Street, CA, 95817, Sacramento, USA.
Deborah SawickyUC Davis Comprehensive Cancer Center, 2279 45th Street, CA, 95817, Sacramento, USA.
Margaret Li KrackelerDepartment of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA, USA.
Brian A JonasUC Davis Comprehensive Cancer Center, 2279 45th Street, CA, 95817, Sacramento, USA.ORCID http://orcid.org/0000-0002-4921-5809
Ryan BeechinorUniversity of California, San Francisco School of Pharmacy, San Francisco, CA, 94143, USA. RBeechinor@ucdavis.edu.ORCID http://orcid.org/0000-0002-2774-0899
UC Davis Comprehensive Cancer CenterUniversity of California, San Francisco · USUniversity of California, Davis · USUniversity of California Davis Medical Center · USUniversity of California System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeVenetoclax combined with a hypomethylating agent (HMA) has become the standard of care for elderly/unfit patients with newly diagnosed acute myeloid leukemia (AML). This study is aimed at characterizing the impact of an interdisciplinary team on the length of stay (LOS) of patients with newly diagnosed AML receiving venetoclax with an HMA.

methodsThis retrospective observational study included patients with AML who received HMA with venetoclax as an initial treatment between December 2015 and July 2021. The primary outcome was the median LOS during induction stratified by HMA. Secondary outcomes included barriers to hospital discharge, incidence of tumor lysis syndrome (TLS), response rates, and utilization of the institution's prescription assistance program (PAP).

resultsSeventy-eight patients were included in our analysis: 51 received azacitidine/venetoclax, and 27 received decitabine/venetoclax. The median LOS from therapy initiation was eight days (range 7-38) for the azacitidine group and six days (range 5-26) for the decitabine group. The most common barriers to discharge were transfusion dependence (33 patients, 42.3%) and insurance coverage (12 patients, 15.4%). Twelve patients (15.3%) had tumor lysis syndrome during hospital admission, and 20 (25.6%) were readmitted during induction. Twenty-three patients (29.5%) required financial assistance for AML care, and a pharmacy-led PAP generated approximately $342,646 in cost savings.

conclusionThe utilization of an interdisciplinary AML team to target early hospital discharge proved to be safe and effective and led to a reduction in costs for the health system. Future research may identify select patients who may be suitable for earlier discharge or outpatient induction.

Indexed as

Leukemia, Myeloid, AcuteTumor Lysis SyndromeAgedAntineoplastic Combined Chemotherapy ProtocolsAzacitidineBridged Bicyclo Compounds, HeterocyclicDecitabineHumansInduction ChemotherapyPatient Care TeamPatient DischargeSulfonamidesTreatment OutcomeAzacitidineBridged Bicyclo Compounds, HeterocyclicDecitabineSulfonamidesvenetoclaxAcute myeloid leukemiaCost-savingsHypomethylating agentsLength of stayMultidisciplinary teamsVenetoclax

Identifiers

PMID36941508
OpenAlexW4328047973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.